other material
confidence high
sentiment positive
materiality 0.85
Galectin Therapeutics presents NAVIGATE trial: belapectin reduces varices, biomarkers improve
GALECTIN THERAPEUTICS INC
- Belapectin 2 mg/kg reduced new varices vs placebo across all ELF risk categories at 18 months; in highest risk (ELF>11.3): 22.7% vs 42.9%.
- Pro-C3 biomarker showed >50% reduction from baseline at 18 months with belapectin 2 mg/kg vs placebo (mean -6.4 vs -4.5 ng/mL).
- Higher proportion of belapectin 2 mg/kg patients achieved ≥20% reduction in YKL-40 (33.8% vs 23.1%); fewer had ≥20% PRO-C4 increase (3% vs 13%).
- At 36 months, cumulative new varices incidence 12.4% (belapectin 2 mg/kg) vs 23.4% (placebo), sustained benefit.
- Safety profile encouraging; adverse events and serious adverse events comparable to placebo, no drug-related SAEs.